Tydra Labs

Tydra Labs, based in Canada, is a biotechnology company specializing in innovative biomaterials, particularly advanced fibrillated chitin derived from crustaceans and fungi for diverse industrial applications. Founded in Vancouver, Canada, Tydra Labs focuses on creating advanced biomaterials. The company has successfully completed its first funding round, raising USD 1. 2 mn in a pre-seed funding round on April 14, 2026, led by Spring Impact Capital and participated in by several other investors.

The founder's history is not specified, and there are no mentions of subsidiary companies or pivots in business strategy. Tydra Labs specializes in advanced biomaterials, focusing on high-performance fibrillated chitin derived from crustacean shells and fungi. This product enhances the mechanical, barrier, and antimicrobial properties of materials without toxic additives. It has applications in agriculture, cosmetics, wound care, and drug delivery systems, targeting markets in North America, Europe, and Asia.

Tydra Labs generates revenue through direct partnerships and B2B transactions, primarily in the food, cosmetics, and pharmaceutical sectors. Clients procure bulk quantities of fibrillated chitin for integration into their products, with an emphasis on competitive pricing to align with industry standards for high-performance biomaterials. In April 2026, Tydra Labs raised USD 1. 2 mn in pre-seed funding to support growth and scaling pilot production.

The company plans to launch new biomaterial products and expand into new geographic markets, specifically targeting North America and Europe. The recent funding will be utilized to further develop these initiatives.